3 Biotech Stocks To Watch This September

Investing Divas
Sep 4, 2018 · 3 min read

With many clinical and regulatory catalysts on the way, the rally we are seeing throughout the biotech sector should gain even more momentum. Last week, every single fund tracking the sector had recorded new highs, and analysts believe that this sentiment could endure for the remainder of the year.

Both the iShares NASDAQ Biotechnology Index (IBB) and the S&P Biotech ETF (XBI) are up around 20%, the Health Care SPDR ETF (XLV) has gained about 17%, while the S&P Pharmaceuticals ETF (XPH) has seen gains of 29% and closed just a penny shy of all-time highs on Friday.

With several biotech companies anticipated to announced news this month, this should add even more steam to the rally we are seeing throughout the sector. Here is a more in depth look at what investors should be watching out for this month.

GT Biopharma, Inc. (GTBP)

GT Biopharma is a clinical stage bio-pharmaceutical company which focuses on developing immune-oncology products using its TriKE and TetraKE NK cell-engager platforms. GT Biopharma’s announcement last week of the start of a combination trial of OXS-1550 and multi-billion-dollar oncology drug, owned by an unnamed Major Pharmaceutical Company, is not something to overlook.

“We are very excited about our progress with GT’s OXS-1550 (DT2219) combined with ibrutinib,” said Dr. Daniel Vallera, GTBP’s head researcher.

Although GTBP has not disclosed the phama company, they revealed the drug. Ibrutinib was developed by Pharmacyclics up to Phase II, then partnered with Johnson & Johnson (JNJ) and Pharmacyclics was acquired by AbbVie (ABBV). More information regarding this collaboration could come out later this month.

Geron Corporation (GERN)

Geron is a clinical stage bio-pharmaceutical company focusing on the development of its telomerase inhibitor, imetelstat, targeting blood disorders with Janssen Biotech, Inc., a subsidiary of Johnson & Johnson (JNJ).

Geron is expecting J&J to announce its decision regarding imetelstat’s clinical program before the end of September. However, J&J is scheduled to hold a conference call for investors on the status of its pharma business on the 13th and many believe their decision will be announced then. J&J continues to list Geron’s drug as a top candidate in its pipeline and the company is supposedly hiring a pricing manager to handle imetelstat’s commercialization.

Amarin Corporation Plc. (AMRN)

Amarin is bio-pharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. The company announced last week said its cardiovascular outcomes study, REDUCE-IT, is now likely to be the next large cardiovascular outcomes study to report results, with top-line results anticipated to be reported before the end of this month.

If Reduce-It hits its primary endpoint, peak sales for Vascepa’s, the company’s first FDA approved candidate, could come close to $2 billion over the next ten years. Analysts expect this biotech’s shares to more than double if this trial pans out.



MIDAM VENTURES LLC., a Florida Corporation has been compensated $200,000.00 by GT Biopharma Inc. for a period beginning July 16, 2018 and ending August 16, 2018 to publicly disseminate information about (GTBP). Midam owns zero shares. Midam may buy or sell additional shares of (GTBP) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.

Stock Market Source

We'll cover everything from marijuana stocks to technology stocks as well as anything in between that could be catching investor attention. Please note that Stock Market Source is now an affiliate of Midam Ventures LLC http://midamir.com/disclaimer/

Investing Divas

Written by

Divas who know how to track & trade w/ profit. Note that this blog is affiliated with Midam Ventures LLC http://midamir.com/disclaimer/

Stock Market Source

We'll cover everything from marijuana stocks to technology stocks as well as anything in between that could be catching investor attention. Please note that Stock Market Source is now an affiliate of Midam Ventures LLC http://midamir.com/disclaimer/

Welcome to a place where words matter. On Medium, smart voices and original ideas take center stage - with no ads in sight. Watch
Follow all the topics you care about, and we’ll deliver the best stories for you to your homepage and inbox. Explore
Get unlimited access to the best stories on Medium — and support writers while you’re at it. Just $5/month. Upgrade